Table 1. Baseline Patient Characteristics.
| Total sample (N = 421) |
Olanzapine (N = 100) |
Quetiapine (N = 94) |
Risperidone (N = 85) |
Placebo (N = 142) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Demographic | ||||||||||
| Age (years) | 77.9 | 7.5 | 78.8 | 7.3 | 77.3 | 8.7 | 78.4 | 7.1 | 77.3 | 7.1 |
| Education (years) | 12.3 | 3.4 | 11.8 | 3.6 | 12.6 | 3.3 | 12.8 | 3.1 | 12 | 3.3 |
| Cognitive | ||||||||||
| MMSE score | 15 | 5.8 | 15 | 5.4 | 14.9 | 6.1 | 15.7 | 6.1 | 14.7 | 5.8 |
| ADAS-cog score 1 | 34.6 | 13.3 | 34.6 | 12.7 | 36.1 | 13.6 | 31.1 | 13.6 | 35.7 | 13.2 |
| BPRS total score | 27.8 | 12.3 | 27 | 11.8 | 28 | 12.3 | 27.7 | 13.6 | 28.2 | 12 |
| Metabolic | ||||||||||
| Weight (pounds) | 150.3 | 31.4 | 148.9 | 36.6 | 153.3 | 30.5 | 151.7 | 31.4 | 148.3 | 28 |
| BMI (kg/m2) | 25.4 | 4.6 | 25.3 | 5.7 | 25.5 | 3.9 | 25.9 | 4.8 | 25.2 | 4 |
| Waist circumference (inches) |
35.6 | 5 | 35.3 | 5.6 | 36.3 | 4.8 | 35.9 | 5.4 | 35.2 | 4.6 |
| Systolic BP (mmHg) | 136.5 | 18.4 | 132.4 | 18.1 | 135.6 | 17 | 136.8 | 19.1 | 139.7 | 18.8 |
| Diastolic BP (mmHg) | 75.7 | 10.4 | 75 | 11.4 | 75.8 | 10.3 | 75.7 | 9.4 | 76.1 | 10.3 |
| HDL (mg/dL) | 53.4 | 15.7 | 52.3 | 15.8 | 52.9 | 14 | 55.6 | 18.3 | 53.3 | 15.1 |
| Triglyceride (mg/dL) 2 | 151.5 | 91.4 | 155.3 | 93.3 | 151.6 | 99.3 | 150.7 | 83.8 | 149.4 | 90.1 |
| Glucose (mg/dL) 2 | 89.2 | 19.2 | 88 | 9.3 | 88.4 | 20.5 | 89 | 10.2 | 90.4 | 25.7 |
| Demographic | N | % | N | % | N | % | N | % | N | % |
| Female | 235 | 56 | 55 | 55 | 50 | 53 | 49 | 58 | 81 | 57 |
| Race | ||||||||||
| White | 331 | 79 | 80 | 81 | 76 | 81 | 68 | 80 | 107 | 76 |
| Black | 75 | 18 | 14 | 14 | 15 | 16 | 15 | 18 | 31 | 22 |
| Other | 13 | 3 | 5 | 5 | 3 | 3 | 2 | 2 | 3 | 2 |
| Married | 249 | 59 | 63 | 63 | 56 | 60 | 49 | 58 | 81 | 57 |
| Number of subjects reaching specific trial period | ||||||||||
| Week 12 | ||||||||||
| Total 3 | 369 4 | 66 | 67 | 67 | 49 | |||||
| Phase 1 | 155 | 41 | 31 | 34 | 49 | |||||
| Week 24 | ||||||||||
| Total | 337 | 49 | 58 | 53 | 24 | |||||
| Phase 1 | 94 | 24 | 23 | 23 | 24 | |||||
| Week 36 | ||||||||||
| Total | 315 | 43 | 45 | 38 | 21 | |||||
| Phase 1 | 78 | 20 | 18 | 19 | 21 | |||||
1
Alzheimer’s Disease Assessment Scale-cognitive subscale score
2
Fasting triglyceride and glucose measures were available among 286 patients with 64, 65, 56, and 101 in the olanzapine, quetiapine, risperidone, and placebo groups, respectively
3
Number of patients reaching trial follow-up regardless of phase
4
Including patients on olanzapine, quetiapine, risperidone, placebo, citalopram, or open-choice medications